Wed, March 5, 2025

by: MarketWatch

Stock Market Today: Dow rises 150 points, S&P 500 and Nasdaq waver as investors digest fresh economic data, potential tariff relief

Stocks are looking to hold an early bounce Wednesday, with focus on economic data, as well as hopes for a potential softer approach on tariffs from President Trump.

by: MSN

AAPL, NVDA, or PLTR: Which Tech Stock Is the Most Attractive Pick?

The ongoing trade wars triggered by the tariffs imposed under the Trump administration are weighing on investor sentiment on technology stocks.

by: MSN

Tesla Stock: Finding a Bottom May Take Time

Forecast|NASDAQ:TSLA] Few people will be happier to see February end than Tesla Inc. (NASDAQ: TSLA) shareholders. The stock had the second-worst performance in its history. And the stock is down 29.5% in 2025.

by: MarketWatch

Here's some good news for you during this horrible week for stocks

Prior to covering personal finance, she was a film critic and entertainment business reporter, writing for Entertainment Weekly, The Dallas Morning News and many more publications. You can follow heron Twitter @bethpinsker.

by: Investopedia

Top Stock Movers Now: Tesla, Best Buy, Walgreens, and More

Major U.S. equities indexes sank at midday Tuesday as new U.S. tariffs against leading trade partners went into effect.

by: Investing

With a 129% YTD gain in the bag, these are our AI's top global picks for March

These global strategies are built on top of the same logic that drove an astonishing +80.94% gain from Tech Titans since launch in November 2023 - that's a massive 42.16% outperformance over the S&P 500. Honestly, what was the last time you got results like these? I'm betting never is the answer...

by: MSN

Beverages, Alcohol, and Tobacco Stocks Q4 In Review: MGP Ingredients (NASDAQ:MGPI) Vs Peers

Let's dig into the relative performance of MGP Ingredients (NASDAQ:MGPI) and its peers as we unravel the now-completed Q4 beverages, alcohol, and tobacco earnings season. These companies' performance is influenced by brand strength,

by: MarketWatch

Avoiding this one sector has been the key to gains for stock investors so far in 2025

Tech has been the play to avoid in 2025, Societe Generale says. Here's what its strategists are recommending instead.

by: MSN

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on a volume-driven,

by: MSN

The Nasdaq Is in a Correction - Here Are 2 Stocks You Can Buy on Sale Right Now

A stock market correction is generally defined as a drop of 10% from recent highs, and the tech-heavy Nasdaq Composite just got there. The Nasdaq has been the best performing major market index for the past two years but has not exactly started 2025 on a high note.

by: Newsweek

How Nancy Pelosi's Stocks Have Performed Under Donald Trump

The Pelosis have a number of stock holdings in Nancy's husband Paul's name. The stocks, which are largely in the technology space, have not seen much growth since Trump's inauguration on January 20. As stock owners and multimillionaires abound in Congress, fears of insider trading and conflicts of interest have lingered.

by: MSN

Trump's Tariffs Take Effect: What Should You Do With Your Investments Right Now?

The Trump administration implemented 25% tariffs against Canada and Mexico on March 4, as well as an additional 10% tariff on goods from China -- bringing the total tariff on Chinese-made goods to 20%.

by: WOPRAI

Short squeeze is starting in shares of TNP at $16.32, after crossing above the $12.475 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SYNL at $11.26, after crossing above the $10.007 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of STRC at $6.6, after crossing above the $2.015 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SOI at $28.77, after crossing above the $9.223 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SMDM at $1.975, after crossing above the $0.245 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SLAMU at $11, after crossing above the $10.123 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SGMS at $106.58, after crossing above the $39.645 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SEAS at $48.66, after crossing above the $42.115 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of RE at $356.71, after crossing above the $277.955 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of RCRT at $1.82, after crossing above the $0.791 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PWFL at $6.31, after crossing above the $4.631 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PRMW at $33.415, after crossing above the $16.578 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PNM at $51.63, after crossing above the $44.368 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PDYPF at $266.66, after crossing above the $159.582 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ORN at $6.601, after crossing above the $6 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ORCC at $15.025, after crossing above the $13.04 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of OFC at $27.04, after crossing above the $25.675 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of OCN at $30.54, after crossing above the $5.651 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of OAS at $104.677, after crossing above the $2.407 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of NYCB at $11.945, after crossing above the $8.285 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of NRZ at $11.695, after crossing above the $8.821 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of NR at $5.53, after crossing above the $4.31 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MTD at $1246.52, after crossing above the $1244.903 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MPLN at $19.35, after crossing above the $3.482 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MMMB at $5.945, after crossing above the $2.634 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of LGI at $16.22, after crossing above the $16.204 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of KNW at $3.15, after crossing above the $0.303 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of JBT at $133.995, after crossing above the $108.054 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ISTR at $18.07, after crossing above the $17.842 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of INT at $28.77, after crossing above the $27.313 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of HTBI at $36.06, after crossing above the $24.618 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of HLMN at $9.41, after crossing above the $9.355 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of GLT at $19.8, after crossing above the $4.695 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ESRT at $8.65, after crossing above the $8.551 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of EPAZ at $0.018, after crossing above the $0.007 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of DGRE at $24.177, after crossing above the $24.123 Trigger Price

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on a volume-driven,

The article from MSN Money discusses the performance of generic pharmaceuticals stocks in the fourth quarter, focusing on Amneal Pharmaceuticals (NASDAQ: AMRX) and comparing it with its peers. Amneal experienced a significant stock price increase of 100% over the last year, driven by a robust Q4 performance where it reported a 13% year-over-year revenue growth to $617.8 million, surpassing expectations. This growth was attributed to strong sales in its generics and specialty segments. However, despite the positive revenue figures, Amneal's net loss widened to $13.7 million from $1.3 million the previous year, due to increased operating expenses and interest costs. The article also mentions that while Amneal outperformed some of its peers in stock price growth, companies like Teva Pharmaceutical Industries and Viatris Inc. faced different challenges, with Teva dealing with legal issues and Viatris focusing on restructuring efforts. Overall, the sector shows mixed results with Amneal standing out for its revenue growth but still grappling with profitability issues.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/savingandinvesting/generic-pharmaceuticals-stocks-q4-in-review-amneal-nasdaq-amrx-vs-peers/ar-AA1Ai0IY